Trial Profile
A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2017
Price :
$35
*
At a glance
- Drugs Spebrutinib (Primary)
- Indications Rheumatoid arthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Celgene Corporation
- 03 Jun 2016 Status changed from active, no longer recruiting to completed.
- 04 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 24 Feb 2015 Planned End Date changed from 1 Nov 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov.